Project Grant R50CA290098
Award Date
8/7/24
Completion Date
7/31/29
Dollars Obligated
$160K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Kansas City, KS 66160, USA
Similar Awards
This $172,197 Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) aims to establish and refine processes to facilitate clinical trials in cancer interception (active cancer prevention) at the University of Kansas Cancer Center (KUCC). Key objectives include: Hiring project navigators to support study approvals for principal investigators in non-oncology departments outside KUCC Training research coordinators in cancer prevention trial processes...
This federal Project Grant award for $194,778 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the optimization of strategies to improve NCI-sponsored clinical trial participation across the Weill Cornell Medicine - Meyer Cancer Center sphere, which serves a diverse population of approximately 6 million patients in the New York City metropolitan area. The principal investigator, Dr. Tagawa, has extensive experience leading and mentoring others on NCI clinical...
This $135,573 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support the following key objectives at the University of Virginia Comprehensive Cancer Center (UVA): Increase UVA's accrual depth and breadth in National Clinical Trials Network (NCTN) and Experimental Therapeutics Clinical Trials Network (ETCTN) clinical trials by identifying and overcoming provider and patient barriers. Increase UVA's leadership and collaboration in...
This Project Grant award from the Department of Defense's Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $564,000.00 to The Institute For Cancer Research, a subsidiary of Temple University, to increase clinical trial enrollment of underrepresented kidney cancer patients by improving access to participation. The award is for a two-year period from September 1, 2023 to August 31, 2025. The Institute For Cancer Research will leverage its...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research federal grant program (CFDA 93.395), provides $113,202 to support research capacity building efforts by Dr. Elie Dib at the Michigan Cancer Research Consortium (MCRC). The key products and services to be delivered through this award include: Contributing to MCRC initiatives aimed at increasing the rate of clinical trials enrollment by minority and underserved populations. Launching safety...
This $620,000 Project Grant, awarded on June 15, 2024 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to elucidate the late effects of radiation in head and neck cancer patients. The research aims to advance scientific knowledge and develop innovative therapies in the field of cancer. As a prime federal grant recipient, KUMCRI has an extensive...
This Cooperative Agreement award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $946,500.00 to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to test the effectiveness of pragmatic strategies to promote high-quality, evidence-based cancer survivorship care for rural adult cancer survivors in primary care practices. The project aims to assess the impact of interventions such as virtual scribes,...
This National Cancer Institute (NCI) Project Grant award under CFDA 93.395 "Cancer Treatment Research" provides $196,267 in funding to the University of California, Irvine (UCI) to advance novel cancer prevention and therapeutic strategies across NCI's clinical trial networks. The award will support the Principal Investigator's leadership roles on key NCI committees, completion of an ongoing Phase III clinical trial focused on preventing colorectal adenomas in a racially/ethnically...
This $132,015 Project Grant award was provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to The Ohio State University. The funding will support efforts to improve enrollment in clinical trials for gynecologic cancers, especially among underrepresented populations. Key activities include: Developing a comprehensive system at The Ohio State University Comprehensive Cancer Center to streamline molecular matching and identification of patients for...
The University of Kansas Medical Center Research Institute, Inc. (KUMCRI) received a $30,000,000 Project Grant award from the U.S. Department of Health and Human Services, Health Resources and Services Administration (HRSA) under the Congressional Directives (CFDA 93.493) program. The award will supplement the construction of a new 205,000 square foot University of Kansas Cancer Center building, which will centralize cancer research, clinical, and population health activities. This building will...